RxSight, Inc.

RxSight primarily generates revenue in the United States, where it focuses its commercial organization and installed base. The company also has approvals in Europe, Canada, Mexico, Singapore, Australia, and South Korea, with subsidiaries in Hong Kong and the Netherlands plus operations in the UK and Germany. International markets are strategically important because premium cataract procedures are larger outside the U.S., but reimbursement and regulatory pathways vary by country.

RxSight depends on adoption of a specialized surgical workflow, regulatory approvals, and effective training of doctors and practice staff. The business also relies on third-party and single-source suppliers for certain components, and its intellectual property and trade secrets are central to its competitive position. As a medical device company, it faces product safety, reimbursement, competition, and commercialization risks that can slow penetration or affect customer confidence.